Skip to main content

Advertisement

Fig. 6 | Journal for ImmunoTherapy of Cancer

Fig. 6

From: Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy

Fig. 6

| In vivo anti-tumor effects of CAI, DMF, 1-MT and the combinations of CAI + DMF and CAI + 1-MT with PD-1 antibody as a positive control drug. BALB/c or C57BL/6 mice were subcutaneously injected with B16 (2 × 105 cells/mouse), C26 (1 × 105 cells/mouse) or 4 T1 (1 × 105 cells/mouse) tumor cells. When the tumor size was 5 × 5 mm, the mice were treated with PBS, CAI, 1-MT, CAI/1-MT, and anti-PD-1 neutralizing antibody or PBS, CAI, DMF, CAI/DMF, and anti-PD-1 neutralizing antibody for 28 days. The tumor growth curves and survival curves for tumor-bearing mice (n = 10) receiving various treatments are shown as indicated. a and b C26 colorectal cancer model. c and d B16 melanoma model. e and f 4 T1 breast cancer model. The data represent the mean ± s.e.m. ***p < 0.001 by one-way ANOVA (a-f, left panels) and Kaplan-Meier survival analysis (a-f, right panels)

Back to article page